Single-isocenter volumetric-modulated Dynamic WaveArc therapy for two brain metastases
| Autor: | Kengo Ogura, Masahiro Hiraoka, Nobutaka Mukumoto, Keiichi Takehana, Tomohiro Katagiri, Takashi Mizowaki, Megumi Uto, Mitsuhiro Nakamura, Yuki Miyabe, Hideaki Hirashima |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Time Factors
medicine.medical_treatment Planning target volume Dose distribution 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine Planning study medicine Humans Arc therapy Radiology Nuclear Medicine and imaging In patient Brain Neoplasms business.industry Radiotherapy Planning Computer-Assisted Isocenter Radiotherapy Dosage Radiation therapy Treatment Outcome 030220 oncology & carcinogenesis Female Radiotherapy Intensity-Modulated Treatment time business Nuclear medicine |
| Zdroj: | Japanese Journal of Radiology. 37:619-625 |
| ISSN: | 1867-108X 1867-1071 |
| DOI: | 10.1007/s11604-019-00849-9 |
| Popis: | A new irradiation technique, volumetric-modulated Dynamic WaveArc therapy (VMDWAT), based on sequential non-coplanar trajectories, can be performed using the Vero4DRT. This planning study compared the dose distribution and treatment time between single-isocenter volumetric-modulated arc therapy (VMAT) with multiple straight non-coplanar arcs and single-isocenter VMDWAT in patients with two brain metastases. Twenty patients with two planning target volumes exceeding 2.0 cm3 were included. Both VMAT and VMDWAT plans were created with single isocenter and a prescribed dose of 28 Gy delivered in five fractions. Target conformity was evaluated using indices modified from the RTOG-CI (mRTOG-CI) and IP-CI (mIP-CI). VMDWAT significantly improved both mRTOG-CI and mIP-CI and reduced the volume of normal brain tissue receiving 25 and 28 Gy compared to VMAT. The two modalities did not significantly differ in terms of the volume of normal brain tissue receiving 5, 10, 12, 15, and 20 Gy. The mean treatment time was significantly shorter in the VMDWAT group. VMDWAT significantly improved dose distribution in a shorter treatment time compared to VMAT in patients treated for two brain metastases. Single-isocenter VMDWAT may thus be a promising treatment for two brain metastases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink